Announcement of the 15 medicines chosen for the second round of negotiations was one of the Biden administration’s final ...

Drugmakers have raised the list prices of more than 800 prescription drugs — ranging from blood pressure medications to cancer treatments — by a median of 4% at the start of this year, The Wall Street ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Novo’s treatments for obesity and diabetes headline the government’s list of medicines that ... Squibb Co., and Amgen Inc.’s psoriasis drug Otezla. Pfizer said the negotiation process discourages the ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Ozempic, Rybelsus and Wegovy top the list of the newest drugs selected for Medicare Part D price negotiation, part of the ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

The talks around drugs including Novo Nordisk's Wegovy, GSK's Trelegy Ellipta, and Pfizer's Xtandi will set Medicare prices ...

NYSE:JNJ) Johnson & Johnson champions first-ever Canadian consensus paper identifying critical gaps in psoriasis care for ...

The Biden administration announced on Friday the selection of the next 15 prescription drugs that will undergo price negotiations between manufacturers and Medicare, three days before President-elect ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...